key: cord-0839933-c4mz6w9r
authors: Sapkal, Gajanan; Yadav, Pragya D.; Ella, Raches; Abraham, Priya; Patil, Deepak Y.; Gupta, Nivedita; Panda, Samiran; Mohan, V. Krishna; Bhargava, Balram
title: Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine
date: 2021-04-30
journal: bioRxiv
DOI: 10.1101/2021.04.30.441559
sha: ef5a42e08bab52fe5be1f7cbcd5adf1d75911788
doc_id: 839933
cord_uid: c4mz6w9r

The emergence of new SARS-CoV-2 variants has been a serious threat to the public health system and vaccination program. The variant of concerns have been the under investigation for their neutralizing potential against the currently available COVID-19 vaccines. Here, we have determined the neutralization efficacy of B.1.1.28.2 variant with the convalescent sera of individuals with natural infection and BBV152 vaccination. The two-dose vaccine regimen significantly boosted the IgG titer and neutralizing efficacy against both B.1.1.28.2 and D614G variants compared to that seen with natural infection. The study demonstrated 1.92 and 1.09 fold reductions in the neutralizing titer against B.1.1.28.2 variant in comparison with prototype D614G variant with sera of vaccine recipients and natural infection respectively.

India has reported cases infected with the SARS-CoV-2 UK variant (B.1.1.7). 1 In this study, we determined the IgG immune response and neutralizing activity of the 19 convalescent sera specimens obtained from the recovered cases of COVID-19 and confirmed for The geometric mean titer (GMT) of an IgG titer for S1-RBD and N protein ELISA was observed to be 794.8 and 4627 respectively for the SARS-CoV-2 recovered individuals. Covaxin recipients showed a GMT IgG titer of 2250 with S1-RBD and 3099 with the N protein compared; the former being significantly high compared to natural infection ( Figure 1A ). The geometric mean titer (GMT) of the neutralizing antibodies (NAb) of the sera with natural infection and Covaxin recipients for the prototype D614G strain was 120.1 and 337.5. In the B.1.1.28.2 variant, the GMT for individuals with natural infection was observed to be 109.2, while that of vaccine recipient was found to be 175.7.

This study shows that the two-dose Covaxin regimen significantly boosted the IgG titer and neutralizing efficacy against both the variants compared to that seen with natural infection. 

The study is approved by the Institutional Biosafety Committee and Institutional Human Ethics Committee of ICMR-NIV, Pune, India

PDY, RE and PA contributed to study design, data collection, data analysis, interpretation and writing and critical review. GS and DYP contributed to data collection, interpretation, writing and critical review. NG, SP, VKM and BB contributed to critical review and finalization of the paper. 

Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum

mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B. 1.1.7): an exploratory analysis of a randomised controlled trial

Safety and efficacy of the ChAdOx1 nCoV-19 (AZD1222) Covid-19 vaccine against the B. 1.351 variant in South Africa

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial

Levels of SARS-CoV-2 Lineage P. 1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination

Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y. V2 (B. 1.351)

We thank the scientific staff of ICMR-NIV, Pune Dr. Anita Shte, Dr. Rima Sahay, Dr. Gururaj